These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapy of glucocorticoid induced osteoporosis].
    Author: Arazzi M, Di Fulvio G, Di Pietro LO, Grabocka X, Longo MO, Micioni G, Pezzutto A, Piscitani L, Schiazza A, Silvestri S, Vigilante G, Amoroso L, Bonomini M.
    Journal: G Ital Nefrol; 2017 Dec 05; 34(Nov-Dec):. PubMed ID: 29207221.
    Abstract:
    Glucocorticoid-induced osteoporosis (GIO) is a major cause of secondary osteoporosis that starts early after the beginning of therapy even for low drug doses. Glucocorticoids are used for the treatment of immunologic nephropathies and in the setting of kidney transplant. In clinical practice, a number of algorithms are available; they allow us to estimate the long-term risk of major osteoporotic fracture; but none of them is specific for GIO. To date, the therapeutic approach comprises both general measures aimed at correcting calcium and vitamin D intake, and drugs (bisphosphonates, teriparatide, hormone replacement therapy, denosumab) that ameliorate bone mineral density and patient outcomes.
    [Abstract] [Full Text] [Related] [New Search]